Other News To Note
Wednesday, September 26, 2012
• Aprea AB, of Stockholm, Sweden, reported positive data from a Phase I/II study with investigational drug APR-246. In the trial, escalating doses of APR-246 were administered as a monotherapy to 22 patients with advanced blood or prostate cancer for up to four consecutive days. Dose-limiting toxicity was shown at plasma levels well above predicted therapeutic plasma levels.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.